GlaxoSmithKline plc Rating Reiterated by Barclays (GSK)
A number of other analysts have also recently weighed in on GSK. Analysts at Deutsche Bank cut their price target on shares of GlaxoSmithKline plc from GBX 1,630 ($27.85) to GBX 1,500 ($25.63) in a research note on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 18th. They now have a GBX 1,650 ($28.20) price target on the stock. Finally, analysts at Credit Suisse reiterated an “underperform” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 18th. They now have a GBX 1,600 ($27.34) price target on the stock. Four analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company’s stock. GlaxoSmithKline plc currently has a consensus rating of “Hold” and an average price target of GBX 1,690.39 ($28.89).
Shares of GlaxoSmithKline plc (LON:GSK) traded down 0.81% during mid-day trading on Thursday, hitting GBX 1469.50. The stock had a trading volume of 12,743,032 shares. GlaxoSmithKline plc has a 52-week low of GBX 1200.668 and a 52-week high of GBX 1733.00. The stock has a 50-day moving average of GBX 1569. and a 200-day moving average of GBX 1609.. The company’s market cap is £70.742 billion.
The company also recently declared a dividend, which is scheduled for Thursday, October 2nd. Investors of record on Wednesday, August 6th will be given a dividend of GBX 19 ($0.32) per share. This represents a yield of 1.28%. The ex-dividend date of this dividend is Wednesday, August 6th.
GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.